Placental cell therapy for COVID-19 shows early promise but trial halted
Disease control
Terminated
This study tested an experimental treatment called CYNK-001, made from natural killer cells derived from placental stem cells, in 7 adults with moderate COVID-19. The goal was to see if these immune cells could safely help fight the virus. The trial was terminated early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC